Akebia Therapeutics (AKBA) FCF Margin (2017 - 2026)
Akebia Therapeutics (AKBA) reported FCF Margin of 39.72% for Q1 2026, down 1599.0% year-over-year from 2.65% in Q1 2025, and down 173.69% quarter-over-quarter from 53.9% in Q4 2025.
Akebia Therapeutics (AKBA) FCF Margin (2017 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 10 years of FCF Margin data on file, last reported at 39.72% in Q1 2026.
- FCF Margin for Q1 2026 came in at 39.72%, down 1599.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 25.83% (up 4469.0% YoY), and the FY2025 annual result was 28.66%, up 5407.0% from the prior year.
- FCF Margin fell to 39.72% in Q1 2026 per AKBA's latest filing, from 53.9% in the prior quarter.
- Over five years, FCF Margin peaked at 69.39% in Q3 2022 and troughed at 98.02% in Q4 2022.
- A 5-year average of 14.53% and a median of 17.89% in 2024 frame the typical range for FCF Margin.
- On a YoY basis, FCF Margin climbed as much as 18481 bps in 2022 and fell as far as 13932 bps in 2022.
- A 5-year view of FCF Margin shows it stood at 98.02% in 2022, then soared by 96 bps to 4.11% in 2023, then slumped by 134 bps to 9.61% in 2024, then soared by 661 bps to 53.9% in 2025, then slumped by 174 bps to 39.72% in 2026.
- Business Quant data shows AKBA's FCF Margin at 39.72% in Q1 2026, 53.9% in Q4 2025, and 47.69% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -5.22% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 12.86% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 46.39% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 16.78% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -2.77% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -429.96% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 13.24% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 32.62% |
| 10 | Akebia Therapeutics | 243.23 Mn | 80.63 Mn | 41.25 Mn | -39.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.72% |
| Dec 31, 2025 | 53.90% |
| Sep 30, 2025 | 47.69% |
| Jun 30, 2025 | 35.57% |
| Mar 31, 2025 | -23.73% |
| Dec 31, 2024 | -9.61% |
| Sep 30, 2024 | -17.89% |
| Jun 30, 2024 | -23.13% |
| Mar 31, 2024 | -59.59% |
| Dec 31, 2023 | -4.11% |
| Sep 30, 2023 | -17.05% |
| Jun 30, 2023 | 6.44% |
| Mar 31, 2023 | -43.84% |
| Dec 31, 2022 | -98.02% |
| Sep 30, 2022 | 69.39% |
| Jun 30, 2022 | -70.79% |
| Mar 31, 2022 | -52.53% |
| Dec 31, 2021 | 41.30% |
| Sep 30, 2021 | -115.41% |
| Jun 30, 2021 | -119.33% |